Wilson Sonsini Goodrich & Rosati advised RayThera on the transaction. RayThera, Inc., a biotechnology company, announced the completion of a $110 million Series A round co-led...
You must be a Standard 1 Year member to access this content.
Cooley advised Vivace Therapeutics, Inc., and Wilson Sonsini Goodrich & Rosati advised Vivace Therapeutics on the patent matters related to the transaction. Vivace Therapeutics, Inc. announced...
You must be a Standard 1 Year member to access this content.
Morrison & Foerster advised Crinetics Pharmaceuticals, Inc. on the offering, Wilson Sonsini Goodrich & Rosati advised Crinetics on patent matters and Cooley advised the underwriters. Crinetics...
You must be a Standard 1 Year member to access this content.
Goodwin Procter and Wilson Sonsini Goodrich & Rosati represented MBX Biosciences, Inc. in the offering, and Davis Polk & Wardwell represented the underwriters. MBX Biosciences, Inc....
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Avidity Biosciences on the deal, and Wilson Sonsini Goodrich & Rosati acted as patent counsel to Avidity. Avidity Biosciences, Inc. (Nasdaq: RNA),...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised MBX Biosciences on patent matters on the transaction. MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, announced a $63.5 million Series...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Avidity Biosciences, Inc. on the offering, and Wilson Sonsini Goodrich & Rosati advised Avidity on patent matters related to the transaction. Cooley...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised vTv Therapeutics on patent matters related to the transaction. vTv Therapeutics, a clinical-stage biopharmaceutical company, announced the closing of a private...
You must be a Standard 1 Year member to access this content.
Cooley advised Janux Therapeutics on the offering and Wilson Sonsini Goodrich & Rosati advised Janux on patent matters. Latham & Watkins advised the underwriters. Janux Therapeutics,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Avidity on patent matters related to the transaction. Avidity Biosciences, Inc. (Nasdaq: RNA) announced that it has agreed to sell 15,224,773...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised XinThera on the transaction. Gilead Sciences announced the acquisition of San Diego-based XinThera, a privately held biotech company. The acquisition...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Tenaya on the deal, while Davis Polk advised the joint book-running managers and representatives of the several underwriters. Clinical stage...
You must be a Standard 1 Year member to access this content.
